Mode
Text Size
Log in / Sign up
N/A N=81

Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer

Skin Cancer · Basal Cell Carcinoma · Squamous Cell Carcinoma

Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcome: Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jan 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects
27,635; 31,219 0.31
SECONDARY
Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Subjects With History of Basal Cell Carcinoma
27,635; 25,031 0.49
SECONDARY
Skin Carotenoid Levels in Subjects With History of Basal Cell Carcinoma Versus Control Group
25,031; 31,219 0.09

Summary

The purpose of this study is to determine the difference of skin carotenoid levels between subjects with previous squamous cell carcinomas (SCC), subjects with previous basal cell carcinomas (BCC) and a control group.

Eligibility Criteria

Inclusion Criteria

  • Subjects between 50 and 75 years old without history of previous SCC or BCC.
  • Fitzpatrick skin types I-IV.
  • Willing and able to understand and sign informed consent.
  • Able to complete study and comply with study procedures

Exclusion Criteria

  • Regular ingestion of supplements containing carotenoids or vitamin A in the past 4 weeks.
  • Use of topical retinoids in the past 4 weeks.
  • Treatment with systemic retinoids in the past 6 months.
  • Dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, palmar psoriasis, hand dermatitis or palmo-plantar keratoderma.
  • Previous history of psoriasis.
  • Clinically significant abnormal findings or conditions, which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
  • Subjects who are known to be pregnant or planning a pregnancy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00836342). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search